Exonics Therapeutics

Exonics Therapeutics operates as a biotechnology company. The company discovers and develops drugs for the treatment of neuromuscular diseases. Exonics' lab has demonstrated the ability to use adeno-associated viruses (AAV) based on CRISPR/Cas9 technology to deliver payloads that can identify and correct exon mutations, which prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers.